Skip to Content

Aytu BioPharma Inc AYTU

Morningstar Rating
$2.90 −0.06 (2.03%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AYTU is trading within a range we consider fairly valued.
Price
$2.91
Fair Value
$1.47
Uncertainty
Extreme
1-Star Price
$84.13
5-Star Price
$6.22
Economic Moat
Qbm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AYTU is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.96
Day Range
$2.822.90
52-Week Range
$1.393.45
Bid/Ask
$0.00 / $0.00
Market Cap
$16.15 Mil
Volume/Avg
25,308 / 26,310

Key Statistics

Price/Earnings (Normalized)
0.30
Price/Sales
0.15
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
150

Valuation

Metric
AYTU
Price/Earnings (Normalized)
0.30
Price/Book Value
0.53
Price/Sales
0.15
Price/Cash Flow
3.35
Price/Earnings
AYTU

Financial Strength

Metric
AYTU
Quick Ratio
0.76
Current Ratio
1.11
Interest Coverage
Quick Ratio
AYTU

Profitability

Metric
AYTU
Return on Assets (Normalized)
−6.73%
Return on Equity (Normalized)
−24.29%
Return on Invested Capital (Normalized)
−16.18%
Return on Assets
AYTU
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ANsxg$90.3 Bil
MKKGY
Merck KGaA ADRPlrrrh$74.8 Bil
HLN
Haleon PLC ADRSqf$38.3 Bil
VTRS
Viatris IncJmjx$16.2 Bil
RDY
Dr Reddy's Laboratories Ltd ADRTjw$13.0 Bil
CTLT
Catalent IncCmzxdtw$10.6 Bil
PRGO
Perrigo Co PLCZtqvg$4.4 Bil
CURLF
Curaleaf Holdings IncJgwbn$3.9 Bil
PBH
Prestige Consumer Healthcare IncCrrymk$3.5 Bil
GTBIF
Green Thumb Industries IncVdvg$3.4 Bil

Sponsor Center